The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection

被引：106

作者：

De Filette, M

Ramne, A

Birkett, A

Lycke, N

Löwenadler, B

Jou, WM

Saelens, X

Fiers, W

机构：

[1] State Univ Ghent VIB, DMBR, B-9052 Ghent, Belgium

[2] Arexis AB, SE-41346 Gothenburg, Sweden

[3] Apovia Inc, San Diego, CA 92121 USA

[4] Univ Gothenburg, Dept Clin Immunol, Gothenburg, Sweden

来源：

VACCINE | 2006年 / 24卷 / 05期

关键词：

M2e-HBc vaccine; CTA1-DD; influenza; mucosal immunity;

D O I：

10.1016/j.vaccine.2005.08.061

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Mucosal vaccination requires effective and safe adjuvants. We have evaluated the non-toxic adjuvant CTA1-DD for mucosal vaccination against influenza. CTA1-DD contain, the enzymatically active CTA1 subunit of cholera toxin (CT) genetically fused to a gene encoding a dimer of the D-fragment from Staphylococcus aureus protein A. CTA1-DD only binds to Ig-receptor carrying cells of the immune system. Nasal administration of the universal influenza vaccine M2e-HBc in combination with CTA1-DD completely protected mice from a potentially lethal infection and significantly reduced morbidity. Sera of mice immunized with M2e-HBc + CTA1-DD revealed IgG subclass profiles consistent with an enhanced Th1-type immunity. When the vaccine was administered intraperitoneally, the adjuvant improved the M2e antibody titer in circulation, but did not significantly reduce the morbidity. (c) 2005 Elsevier Ltd. All rights reserved.

引用

页码：544 / 551

页数：8

共 52 条

[31] Sequence comparison between the extracellular domain of M2 protein human and avian influenza A virus provides new information for bivalent influenza vaccine design [J].

Liu, WL ;

Zou, P ;

Ding, J ;

Lu, Y ;

Chen, YH .

MICROBES AND INFECTION, 2005, 7 (02) :171-177

[32] ADP-ribosylating bacterial enzymes for the targeted control of mucosal tolerance and immunity [J].

Lycke, N .

ORAL TOLERANCE: NEW INSIGHTS AND PROSPECTS FOR CLINICAL APPLICATION, 2004, 1029 :193-208

[33]

MAASSAB HF, 1999, VACCINES, P909

[34] The value of a database in surveillance and vaccine selection [J].

Macken, C ;

Lu, H ;

Goodman, J ;

Boykin, L .

OPTIONS FOR THE CONTROL OF INFLUENZA IV, 2001, 1219 :103-106

[35]

MORTON DB, 1995, LAB ANIMALS INTRO EX

[36] Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity [J].

Moyron-Quiroz, JE ;

Rangel-Moreno, J ;

Kusser, KR ;

Hartson, L ;

Sprague, F ;

Goodrich, S ;

Woodland, DL ;

Lund, FE ;

Randall, TD .

NATURE MEDICINE, 2004, 10 (09) :927-934

[37]

Muszkat M, 2000, J MED VIROL, V61, P100, DOI 10.1002/(SICI)1096-9071(200005)61:1&lt

[38]

100::AID-JMV16&gt

[39]

3.0.CO

[40]

2-5

← 1 2 3 4 5 6 →